HIGHLIGHTS
- •The recently approved and recommended tyrosine kinase inhibitor (TKI) treatments tepotinib and capmatinib offer efficacious and tolerable treatment options for adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping in the US.
- •This study assessed the cost-effectiveness of tepotinib versus capmatinib for this patient population in frontline, subsequent line, and any setting (overall), from a US Medicare payer perspective.
- •Tepotinib could be cost-effective versus capmatinib in treating adults with metastatic NSCLC harboring METex14 skipping in frontline settings and overall, whereas cost-effectiveness in subsequent lines depends on willingness-to-pay for additional quality-adjusted life-years.
ABSTRACT
Objectives
Methods
Results
Conclusion
Keywords
Article info
Publication history
Publication stage
In Press Accepted ManuscriptFootnotes
Précis: From the US Medicare perspective, this study shows that tepotinib could be cost-effective relative to capmatinib in treating patients with mNSCLC harboring METex14 skipping.
Methods of Interest: Clinical Outcomes Assessment: Outcomes = Economic < Methods of Interest; Economic: trial-based < Methods of Interest
Author disclosures: VIH-2022-0558
Author Contributions:
Concept and design: Yang, Vioix, Sachdev, Stargardter, Tosh, Pfeiffer
Acquisition of data: Yang, Vioix, Sachdev, Stargardter, Tosh, Paik
Analysis and interpretation of data: Yang, Vioix, Sachdev, Stargardter, Tosh, Pfeiffer, Paik
Drafting of the manuscript: Yang, Vioix, Sachdev, Stargardter, Tosh, Paik
Critical revision of the paper for important intellectual content: Yang, Sachdev, Tosh, Stargardter, Pfeiffer, Paik
Statistical analysis: Sachdev
Provision of study materials or patients: Yang
Obtaining funding: Yang, Vioix, Administrative, technical, or logistic support: Yang, Sachdev, Stargardter, Tosh,
Supervision: Yang, Vioix, Tosh
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Conflict of interest disclosures:
Drs Yang, Vioix, and Pfeiffer are employees at EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany. Mr Sachdev, Dr Stargardter, and Dr. Tosh reported receiving 'personal fees' from their employer Evidera (salary) and 'other' payments from EMD Serono for collaboration on this project and article. Paul Paik reported receiving personal fees from Takeda, EMD Serono, Mirati, Xencor, CrownBio, and Novartis, outside the submitted work.
Funding/Support: Funding for this study and article was provided by EMD Serono and the healthcare business of Merck KGaA, Darmstadt, Germany, who contracted with Evidera for services on this project and with Evidera and Syneos Health UK on the manuscript.
Role of the funder: EMD Serono and the healthcare business of Merck KGaA, Darmstadt, Germany were involved in the study design; the collection, analysis, and interpretation of data; the review of article; and the decision to submit for publication.
Acknowledgements: The authors thank Apoorva Ambavane and Madhav Mittal at Evidera who contributed towards the conceptualization and development of the cost-effectiveness model (CEM), and Chiara Lee at Syneos Health, London, UK for assistance in the editing and formatting of the manuscript.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy
